Bristol-Myers to Buy Inhibitex for $2.5 Billion – Wall Street Journal

Bristol-Myers to Buy Inhibitex for $ 2.5 Billion
Wall Street Journal
Inhibitex makes drugs for infectious diseases, including bacterial and viral infections such as shingles and chronic hepatitis C. Shares of Inhibitex closed Friday at $ 9.87 a share, giving the company a market capitalization of roughly $ 773 million.
Bristol-Myers Squibb to Acquire InhibitexMarketWatch (press release)
Bristol-Myers plans $ 2.5bn drugs mergerCITY A.M.
BMS offers $ 2.5bn to make Inhibitex its latest 'pearl'PMLiVE

all 266 news articles »

shingles disease – Google News